Buchumschlag

Geriatric assessment of older patients receiving Trabectedin in first-line treatment for advanced soft tissue Sarcomas: the E-TRAB study from the German Interdisciplinary Sarcoma Group (GISG-13)

E-TRAB was a non-interventional, prospective trial investigating the feasibility and predictive value of geriatric assessments (GA) in older STS patients treated with trabectedin as first-line therapy. Primary endpoints were overall survival (OS), quality of life and individual clinical benefit asse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kasper, Bernd (VerfasserIn) , Pink, Daniel (VerfasserIn) , Rothermundt, Christian (VerfasserIn) , Richter, Stephan (VerfasserIn) , Augustin, Marinela (VerfasserIn) , Kollar, Attila (VerfasserIn) , Kunitz, Annegret (VerfasserIn) , Eisterer, Wolfgang (VerfasserIn) , Gaidzik, Verena (VerfasserIn) , Brodowicz, Thomas (VerfasserIn) , Egerer, Gerlinde (VerfasserIn) , Reichardt, Peter (VerfasserIn) , Hohenberger, Peter (VerfasserIn) , Schuler, Markus K. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 28 January 2024
In: Cancers
Year: 2024, Jahrgang: 16, Heft: 3, Pages: 1-17
ISSN:2072-6694
DOI:10.3390/cancers16030558
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers16030558
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/16/3/558
Volltext
Verfasserangaben:Bernd Kasper, Daniel Pink, Christian Rothermundt, Stephan Richter, Marinela Augustin, Attila Kollar, Annegret Kunitz, Wolfgang Eisterer, Verena Gaidzik, Thomas Brodowicz, Gerlinde Egerer, Peter Reichardt, Peter Hohenberger and Markus K. Schuler
Beschreibung
Zusammenfassung:E-TRAB was a non-interventional, prospective trial investigating the feasibility and predictive value of geriatric assessments (GA) in older STS patients treated with trabectedin as first-line therapy. Primary endpoints were overall survival (OS), quality of life and individual clinical benefit assessed by the patient-reported outcome measures QLQ-C30 and PRO-CTCAE. Further, several GA tools were applied and correlated with clinical outcomes and treatment-related toxicities. The final analyses included 69 patients from 12 German-speaking sites. The median age of patients was 78 years (range: 55 to 88). Baseline data on PROs and GA identified a diverse population of older patients with respect to their global health status, although a large proportion of them suffered from limitations, required geriatric help and had a high risk of morbidity. The Cancer and Age Research Group (CARG) score classified 38%, 29% and 23% of the patients with low, intermediate and high risks for therapy-related side effects, respectively. Median OS was 11.2 months [95%CI: 5.6; 19.4]. The study confirmed that trabectedin as first-line treatment in older patients with STS has an acceptable and manageable safety profile. Potential prognostic factors for clinical outcome and therapy-related toxicity were identified among the GA tools. Long Timed Up and Go (TUG) showed a significant correlation to OS and early death, whereas a high CARG score (>9) was associated with an increase in unplanned hospitalizations and the incidence of toxicities grade ≥ 3.
Beschreibung:Gesehen am 25.06.2024
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers16030558

Ähnliche Einträge